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Abstract: Fibromyalgia syndrome is a chronic disease of widespread and debilitating pain
whose cause is unknown and whose risk factors are poorly understood. It is often comorbid with
rheumatoid and other pain disorders as well as psychiatric disorders such as anxiety and depression.
Although they are not officially approved for this indication, antiepileptics and antidepressants
are often used to treat fibromyalgia. The tricyclic antidepressants (TCAs), particularly
amitriptyline, are among the most common treatment strategies. Because of the poor tolerability
of the tricyclics, the newer antidepressants have been widely tested in fibromyalgia. The selective
serotonin reuptake inhibitors (SSRIs) and the reversible monoamine oxidase inhibitors do not
seem to be particularly helpful. The serotonin and norepinephrine reuptake inhibitors (SNRIs),
duloxetine and milnacipran, on the other hand, have been shown in placebo-controlled trials to
offer significant relief to patients suffering from fibromyalgia. Although no direct comparative
studies have been performed, these compounds appear to be as effective as the TCAs but much
better tolerated. The effectiveness of the SNRIs as well as other dual acting antidepressants,
such as mirtazapine, but not the SSRIs, implies that a dysfunction of both serotonin and
norepinephrine neurotransmission probably exists in fibromyalgia. The effectiveness of
antidepressants appears to be independent of their effect on comorbid depression.
Keywords: fibromyalgia syndrome, FMS, pain, depression, antidepressants, norephinephrine,
serotonin
Introduction
After osteoarthritis, fibromyalgia syndrome (FMS) is the second most common condition
seen by rheumatologists with an estimated prevalence in the general population of 2%–
4%. FMS is a syndrome characterized by a chronic widespread debilitating musculo-
skeletal pain and stiffness throughout the body (White and Harth 2001; Neumann and
Buskila 2003). Etiology and specific risk factors of FMS are poorly understood but most
patients (80%) are female and frequency tends to increase through middle age and then
to decline (White and Harth 2001). The severe disability caused by FMS has been
estimated to be comparable to that reported for other rheumatic disorders such as
osteoarthritis or rheumatoid arthritis (Hawley and Wolfe 1991), inflammatory myopathies
(Sultan et al 2002), and systemic lupus erythematosus (Tench et al 2002). Since generalized
pain may be present in other rheumatic entities, diagnosis is not easy. Different rheumatic
and non-rheumatic diseases overlap or may be confused with FMS (Martinez-Lavin et
al  2001).
Diagnostic criteria for FMS (Wolfe et al 1990) require the presence, for at least 3
months, of widespread chronic pain as judged by pain upon palpation at 11 or more of
18 tender points. In addition to pain, patients with FMS complain of fatigue, sleep
disturbances, morning stiffness, depressed mood and cognitive and memory
disturbances sometimes referred to as “fibro fog”. In addition headaches, irritable bowel
syndrome, painful menstrual periods, numbness or tingling of the extremities, restless
legs syndrome, temperature sensitivity and a variety of stress-related symptoms andNeuropsychiatric Disease and Treatment 2006:2(4) 538
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neuroendocrinological and immunological dysfunctions are
frequently associated with FMS (Henriksson 2003). FMS may
be triggered by different stressors (Buskila and Neumann 2002)
such as physical trauma, infectious diseases including hepatitis
C, Lyme disease, coxsackie B infection, HIV, and parvovirus
infection (Barkhuizen 2002), endocrine disorders, immune
activation, and emotional distress. Several studies have
shown that FMS tends to aggregate in families (Yunus 1998;
Arnold et al 2004).
In contrast to what was originally thought, the
pathophysiology of FMS appears to reside not in peripheral
musculoskeletal alterations (Olsen and Park 1998), but in
abnormalities of the central pain processing mechanisms
(Bennett 1999, 2005). Cytokines, which are involved in immune
responses as well as the regulation of cell growth and repair,
also play a role in the expression of pain. In FMS, the cytokines
IL-1, IL-6 and IL-8 have been suggested to be dysregulated
(Wallace 2006).
Pathways and modulation of pain perception have been
described by Kranzler et al (2002) and by Briley and Moret
(2003). Nociceptive input is conducted from the periphery to
the spinal cord and to brain centers involved in pain
perception. Neurokinins, such as substance P and neurokinin
A, are released from the peripheral afferent fibers (PAF) and
act on neurokinin receptors, such as the NK1 receptor, in the
dorsal horn of the spinal cord. The neurokinins are co-released
with the excitatory transmitter, glutamate, which acts at
postsynaptic NMDA (N-methyl-D-aspartate) and AMPA
(α-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid)
receptors also localized on neurons in the dorsal spinal cord.
The release of these transmitters is modulated by both
inhibitory α2-adrenergic and µ-opioid receptors and excitatory
serotonin (5-HT)3 receptors present on PAF. Inhibitory α2-
adrenergic,  µ-opioid and 5-HT1A are also present
postsynaptically on the dorsal horn neuron with inhibitory γ-
aminobutyric acid (GABA)A/B receptors. These various
receptors are activated by neurotransmitters such as 5-HT,
norepinephrine (NE), glutamate, GABA, and enkephalines.
Any of the multiple steps of these pathways can be the
site of alterations leading to a state of chronic pain. Brain
imaging studies show direct evidence of altered pain
processing in FMS (Mountz et al 1995; Bradley et al 2002;
Gracely et al 2002). Pain perception from a normally innocuous
stimulus (allodynia) and an increased sensitivity to painful
stimuli (hyperalgesia) characterize nociceptive processing in
patients with FMS (Graven-Nielsen et al 1999; Staud et al
2001). Studies that have shown that patients experience
increased sensitivity to mechanical, thermal, and electrical
stimulation (Arroyo and Cohen 1993; Granges and Littlejohn
1993; Sorensen et al 1998; Gracely et al 2002; Staud et al 2003)
support the hypothesis that FMS is a disorder characterized
by an activation of cortical or subcortical pain processing.
Modified temporal summation of pain stimuli (wind-up) or
sensitization (Geisser et al 2003; Staud et al 2003) occurring at
the level of the PAF-dorsal horn neuron synapse, is typical of
FMS and reflects an increased response of the dorsal horn
neuron to tonic, peripheral nociceptive input. Allodynia and
hyperalgesia observed in FMS probably result from similar
enhanced responses (Herrero et al 2000).
The hypothalamic-pituitary-adrenal (HPA) axis is one of
the major stress response systems in the body. Changes in
the HPA axis and stress-response abnormalities have been
shown in FMS (Crofford 1998; Neeck and Crofford 2000) and
other chronic pain disorders (McBeth et al 2005). FMS often
develops in conjunction with, or is worsened by, hormonal
imbalances indicating a disruption in the body’s stress-
response systems. Crofford et al (1996) have proposed that
FMS should be considered as a “stress-associated syndrome”.
Levels of the stress hormone, cortisol, have been reported to
be modified in patients with FMS. Higher baseline levels of
cortisol have been reported in patients with FMS compared
with controls (Catley et al 2000). Lowered cortisol levels have,
however, also been observed in patients with FMS (Gur et al
2004; Fries et al 2005), one study showing a significant
correlation between cortisol levels and number of tender
points in FMS patients (Gur et al 2004). These conflicting
results have led to suggestions that the HPA axis may be
either hyperactive or hypoactive (Kranzler et al 2002). Fatigue,
sleep disturbance, the presence of depressive symptoms, and
the age of the patient all influence cortisol levels so that it is
difficult to interpret these data in terms of cause or effect.
Sleep disturbances occur frequently in patients with FMS.
An increase in sleep latency, low sleep efficiency, a decrease
in slow-wave sleep, an increase in alpha sleep (stage 1), and
an increase in awakenings have all been reported (Roizenblatt
et al 2001). The occurrence of daytime hypersomnolence in
patients is linked to a greater severity of FMS symptoms and
to more severe polysomnographic alterations (Sarzi-Puttini et
al 2002).
Fatigue is also an important symptom of FMS that can be
mild in some patients and yet incapacitating in others. The
fatigue has been described as “brain fatigue”, in which
patients feel totally drained of energy. It has also been referred
as “brain fog”. Many patients describe this situation byNeuropsychiatric Disease and Treatment 2006:2(4) 539
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saying that they feel as though their arms and legs are tied to
concrete blocks, and they have difficulty concentrating. With
the introduction of different instruments (Mease 2005) it is
now possible to quantify various types of physical and
emotional fatigue.
FMS and major depression commonly co-occur; 20%–40%
of patients diagnosed with FMS also suffer from depression,
with a lifetime prevalence of up to 70% (Epstein et al 1999;
Hudson et al 1985, 1992). A more recent study (Kassam and
Patten 2006) conducted in a large sample from the general
population has shown that the annual prevalence of major
depression was three times higher in subjects with FMS
(22.2%) than in those without FMS (7.2%). There is strong
evidence for an association between FMS and major
depressive disorder, including overlapping symptomatology,
similar pattern of comorbid disorders, high rates of major
depressive disorder among relatives of patients with FMS,
similar pattern of responses to psychological tests and rating
scales, and the high lifetime rates of mood disorders in FMS
(Hudson and Pope 1996). FMS co-aggregates with major mood
disorder in families (Arnold et al 2004), suggesting that mood
disorders and FMS may share some of the inherited genetic
factors possibly involved in the etiology of both disorders.
Similar biological changes have been found in both disorders,
including disturbed HPA-axis, modified responses to NE
(Adler et al 1999) and decreased cerebral spinal fluid levels of
NE (Russell et al 1992a). Sleep abnormalities in FMS are similar
to those associated with 5-HT dysfunction (Moldofsky et al
1975) frequently found in depressed patients. Low serum 5-
HT concentrations and altered density of 5-HT transporter
binding sites (determined with [3H]imipramine or
[
3H]paroxetine) in postmortem brain tissue and in platelets of
drug-free FMS patients (Legangneux et al 2001; Russell et al
1992b; Owens and Nemeroff 1994) as well as the possible
association of the disease with the short form of 5-HT transporter
(considered to be a risk factor for depression) (Offenbaecher et al
1999; Cohen et al 2002) further reinforce the hypothesis of an
association between FMS and depression.
Fibromyalgia can be classified as a “functional somatic
syndrome”. This classification includes a number of
overlapping syndromes such as irritable bowel syndrome
(IBS), chronic fatigue syndrome, and more than 10 other
syndromes which all strongly overlap with depression and
anxiety (Weir et al 2006). Recent evidence suggests that
genetic and familial factors participate in the pathogenesis of
these syndromes and that fibromyalgia and other functional
somatic syndromes may share a number of heritable
pathophysiologic features (Buskila et al 2005). The
hyperalgesia experienced in IBS is thought to result, at least
partially, from sensitization of spinal cord dorsal horn neurons
(Price et al 2006) and in this respect its pharmacopathology
probably has certain features in common with fibromyalgia.
In fact, patients with fibromyalgia are 3–4 times more likely to
suffer from co-morbid IBS than the general population (Kurland
et al 2006; Vandvik et al 2006; Weir et al 2006).
Treatment of fibromyalgia
The multifaceted nature of the disease makes FMS difficult to
treat. Determination of efficacy and the definition of response
are also difficult. Improvement of pain is the most common
outcome measure, usually evaluated with visual analog scales.
Fatigue, sleep, and global well-being are also evaluated with
self-administered instruments. The self-reported, Fibromyalgia
Impact Questionnaire (FIQ) subscales assess various
symptoms and collectively give an estimation of overall
function (Burckhardt et al 1991; Dunkl et al 2000), although
most researchers accept that the instrument has significant
limitations (Bennett et al 2005). The different subscales of the
FIQ determine physical functioning, work status, depression,
anxiety, morning tiredness, pain, stiffness, fatigue, and well-
being during the preceding week. Psychological function is
evaluated with FIQ subscales for depression and anxiety.
Standard depression scales such as Hamilton Depression
Rating Scale, Montgomery Asberg Depression Rating Scale
or the Beck Depression Inventory are also frequently used.
FMS is generally refractory to many of the therapies that
have been tried (Crofford and Clauw 2002; Rao and Clauw
2004). A certain number of non-pharmacologic treatments
including psychotherapy appear, however, to offer some relief
in some patients (Leventhal 1999; Goldenberg et al 2004; Sarac
and Gur 2006). Although no drugs are currently approved for
FMS by health authorities of any country, a broad array of
medications is routinely used. For many, there is no scientific
evidence of efficacy, while evidence for efficacy of many others
is weak (Leventhal 1999; Goldenberg et al 2004). Modest,
although statistically significant, efficacy has been
demonstrated for the opiate analgesic, tramadol, alone (Biasi
et al 1998) or combined with the analgesic antipyretic,
acetaminophen (Bennett et al 2005). The most convincing
demonstration of activity of a non-antidepressant drug has
been with pregabalin, an antiepileptic drug, alpha(2)-delta ligand
acting on GABA receptors, which is already approved in many
countries for the treatment of neuropathic pain. A multicenter,
double-blind, 8-week, randomised clinical trial comparingNeuropsychiatric Disease and Treatment 2006:2(4) 540
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pregabalin (450 mg/day) with placebo in 529 patients with
FMS showed that pregabalin was effective in reducing
symptoms of pain, disturbed sleep, and fatigue compared with
placebo. Reduction of pain intensity by at least 50% was
achieved in 29% of patients with pregabalin compared with
only 13% on placebo. Improvements in global measures
and health-related quality of life were also greater with
pregabalin (Crofford et al 2005).
Antidepressant treatment of
fibromyalgia
The frequent comorbidity of FMS with depression has
naturally favored the use of antidepressant medication in FMS.
Antidepressants are now the most widely studied and, for
certain, the most successful therapy of fibromyalgia
(Goldenberg et al 2004; Bennett 2005).
Monoamine oxidase inhibitors
There is no evidence that monoamine oxidase inhibitors
(MAOI) are effective in the treatment of FMS. The only study
to investigate the activity of irreversible MAOIs in FMS found
them to offer no benefit with the possible exception of
combination of MAOI and 5-HTP (Nicolodi and Sicuteri 1996).
The stress- and/or diet-related adverse events seen in this
study indicate that these drugs are not suitable for FMS
patients. A study (see below for details) comparing the
reversible MAOI, moclobemide, and the tricyclic
antidepressant (TCA), amitriptyline, and placebo in the
treatment of FMS in women without psychiatric disorder,
concluded that moclobemide was not helpful (Hannonen
et al 1998).
Tricyclic antidepressants
In 1986, two randomized placebo-controlled trials
demonstrated the effectiveness of amitriptyline in FMS. The
administration of amitriptyline (50 mg/d at bedtime) to 27
patients with FMS for 9 weeks resulted in significant
improvements in pain, stiffness and sleep compared to 32
patients treated with placebo (Carette et al 1986). In the second
study (Goldenberg et al 1986) 62 patients with FMS received
either amitriptyline (25 mg/d at bedtime), the non-steroidal
anti-inflammatory drug, naproxen (500 mg twice daily), both
amitriptyline and naproxen, or placebo for
6 weeks. Patients administered amitriptyline had significant
improvement in pain, sleep difficulties, fatigue on awakening,
and tender point score compared to placebo. There was no
significant difference in pain improvement between patients
taking amitriptyline alone or amitriptyline with naproxen.
Scudds et al (1989) administered 36 patients with a low flexible
dose (<50 mg/d) of amitriptyline for 10 weeks and found
significant improvements in pain, tender point sensitivity and
patient assessment of well-being compared with placebo. In a
12-week study 130 female FMS patients were randomized to
receive amitriptyline (25–37.5 mg/d), the reversible monoamine
oxidase inhibitor, moclobemide (450–600 mg), or placebo
(Hannonen et al 1998). Various measures including general
health, pain, sleep quality and quantity, and fatigue as
estimated by visual analogue scales were significantly more
improved in patients on amitriptyline than in the other groups.
Moclobemide improved pain, but had no effect on other
parameters including sleep. The tricyclic compound
cyclobenzaprine, which differs from amitriptyline by only one
double bond, is a muscle relaxant and not an antidepressant.
It has also been shown to be effective in reducing the
symptoms of FMS when administered at 10–40 mg/d at bedtime
in randomized controlled trials lasting 6–12 weeks (Carette et
al 1994; Bennett et al 1998; Tofferi et al 2004). A longer study
(Carette et al 1994), which followed 208 patients treated with
amitriptyline, cyclobenzaprine, or placebo for 6 months
reported significant clinical improvement for both tricyclic
drugs although initial improvement was lost at 6 months.
Two meta-analyses have concluded that tricyclic
antidepressants (amitriptyline, maprotiline, chlorimipramine,
dothiepin) were better than placebo in the treatment of FMS
(Table 1). From 16 randomized, placebo-controlled trials
involving TCAs, Arnold et al (2000) found that 9 were
appropriate for data extraction. Overall, the quality of the
studies was good. Compared with placebo, effect sizes of
TCAs, calculated for patient and physician global assessment,
pain, fatigue, sleep, tenderness, stiffness, were significantly
larger than zero. Quality of sleep was the most improved
measurement, whereas stiffness and tenderness had only
modest improvement. There was a significant clinical response
in 25%–37% of patients although the overall degree of efficacy
was modest in most studies. A second meta-analysis found
that the odds ratio for improvement with antidepressants
(mainly TCAs but also including some other antidepressants)
was 4.2 (95% confidence interval, 2.6–6.8), and pain, sleep,
fatigue, and sense of well-being were improved, but there was
no improvement in trigger points (O’Malley et al 2000).
Thus there is strong evidence for efficacy of the TCAs
especially amitriptyline in FMS (Goldenberg et al 2004;
Offenbaecher and Ackenheil 2005). It should be noted,
however, that the effect size of all the studies was small. TheNeuropsychiatric Disease and Treatment 2006:2(4) 541
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Table 1 Principal placebo-controlled trials of antidepressants in the treatment of fibromyalgia syndrome
Study Treatment Daily dose n Design Duration Outcome
groups (mg/d)
Carrette et al 1986 amitriptyline 50 27 parallel 9 wks AMI > PL
placebo 32
Goldenberg et al 1986 amitriptyline 25 16 parallel 6 wks AMI > PL
placebo 16
Bibolotti et al 1986 maprotiline 75 37 cross-over 3 x 3 wks Inconclusive, very high drop out
chlorimipramine 75
placebo
Caruso et al 1987 dothiepin 75 27 parallel 8 wks DOT > PL
placebo 25
Scudds et al 1989 amitriptyline 50 36 cross-over 2 x 4 wks AMI > PL
placebo
Jaeschke et al 1991 amitriptyline 5–50 23 N-of-1 25% significant positive response
Carrette et al 1994 amitriptyline 50 98 parallel 26 wks AMI = CYC > PL
cyclobenzaprine 30 86
placebo 96
Wolfe et al 1994 fluoxetine 20 21 parallel 6 wks FLU = PL
placebo 21
Norregaard et al 1995 citalopram 20–40 22 parallel 8 wks CIT = PL
placebo 21
Ginsberg et al 1996 amitriptyline 25 24 parallel 8 wks AMI > PL
placebo 22
Goldenberg et al 1996 amitriptyline + PL 25 19 Cross-over 4 x 6 wks FLU + AMI > AMI = FLU > PL
amitriptyline + 25+20
fluoxetine
fluoxetine + PL 20
placebo
Hannonen et al 1998 amitriptyline 23–37.5 43 parallel 12 wks AMI > MOC = PL
moclobemide 450–600 42
placebo 45
Anderberg et al 2000 citalopram 20–40 21 parallel 16 wks CIT = PL
placebo 19
Arnold et al 2002 fluoxetine 20–80 32 parallel 12 wks FLU > PL
placebo 28
Zijlstra et al 2002 venlafaxine 75 45 parallel 6 wks VEN = PL
placebo 45
Purcell et al 2004 paroxetine 12.5–62.5 58 parallel 12 wks Globally PAR > PL but no effect
placebo 58 on VAS pain scores
Arnold et al 2004 duloxetine 120 104 parallel 12 wks DUL > PL
placebo 103
Arnold et al 2005 duloxetine 60 118 parallel 12 wks DUL(60) = DUL(120) > PL
duloxetine 120 116
placebo 120
Gendreau et al 2005 milnacipran (od) 200 51 parallel 12 wks MIL > PL
milnacipran (bid) 200 46
placebo 28
Note: Bold print highlights the absence of effect.
Abbreviations: AMI, amitriptyline; CIT, citalopram; CYC, cyclobenzaprine; DOT, dothiepin; DUL, duloxetine; FLU, fluoxetine; MIL, milnacipran; MOC, moclobemide;
PAR, paroxetine; PL, placebo; VEN, venlafaxine; wks, weeks.Neuropsychiatric Disease and Treatment 2006:2(4) 542
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doses used were considerably lower than those considered
necessary for an optimal effect in major depression and no
studies of amitriptyline have carried out a dose-range study.
Would higher doses of TCAs produce larger therapeutic
effects? Would the greater side-effects to be expected at higher
doses be acceptable? Clearly more effective and better
tolerated drugs are clearly needed. This line of thinking led to
testing the selective serotonin reuptake inhibitors (SSRI) in
FMS.
Selective serotonin reuptake inhibitors
Fluoxetine
In a 6-week double-blind placebo-controlled study, 42 women
suffering from FMS were randomized to receive either placebo
or fluoxetine at 20 mg/d (Wolfe et al 1994). At end-point
fluoxetine was ineffective on all measures except depression
scores. A better outcome was found, however, in another study
using higher doses. Sixty women outpatients with FMS were
randomly assigned to receive fluoxetine
(10–80 mg/d) or placebo for 12 weeks in a double-blind, parallel-
group, flexible-dose study. The mean dose of fluoxetine
administered was 45 ± 25 mg/d, which is a higher dose than
that usually prescribed to depressed patients, significantly
improved the Fibromyalgia Impact Questionnaire (FIQ) total
score, the FIQ pain score, and the FIQ fatigue and depression
scores (Arnold et al 2002). No statistically significant difference
was found, however, for pain at tender points and total myalgic
scores between the fluoxetine group and the placebo group.
A 6-week, randomized, double-blind, crossover study
evaluated the effect of fluoxetine (20 mg), amitriptyline
(25 mg), a combination of fluoxetine and amitriptyline, or
placebo, in 19 patients with fibromyalgia (Goldenberg et al
1996). Both drugs improved scores on the FIQ and on the
VAS for pain, global well-being, and sleep disturbances, and
the combination of the 2 treatments worked better than either
medication alone.
Similarly, pain intensity, the number of painful tender points,
tender points index and morning stiffness were improved with
fluoxetine (20 mg/d) combined with cyclobenzaprine (10 mg/
d) in a 12-week study of 21 females with FMS (Cantini et al
1994) compared with cyclobenzaprine alone.
All of the above studies are small and can only be
considered suggestive. It appears possible that doses higher
than those usually used for depression or combination of
fluoxetine with other active compounds may result in some
relief of symptoms in patients with FMS.
Citalopram
Two randomized, double blind, placebo-controlled studies
have shown that citalopram was ineffective. In the first, 22
patients with fibromyalgia were treated with citalopram at a
dose of 20 mg/d while 21 received placebo, for 4 weeks
(Norregaard et al 1995). If the subjects did not show a marked
improvement after 4 weeks the dosage of citalopram was
increased to 40 mg for a further 4 weeks. At the end of treatment
(8 weeks) no differences were observed between the groups.
The second study included 40 female patients, 21 patients in
the citalopram (20–40 mg/d) groups, and 19 in the placebo
group (Anderberg et al 2000). Citalopram was ineffective on
all measures except pain visual analogue scale at 2 months
but not at the 4-month end-point. Measurement of pain with
the FIQ also showed some significant differences at the end
of the trial. Taken together these trials give little indication of
any utility of citalopram in the treatment of FMS.
Paroxetine
There are no published studies of paroxetine in FMS. A double-
blind, placebo-controlled, 12-week trial with 116 patients has
been presented as a poster (Purcell et al 2004), which is not
yet published in full. Response was defined as an
improvement of 25% or more on the total FIQ score rather
than the more usual 50%. Using this definition the study found
significantly more responders with controlled release
paroxetine (12.5–62.5 mg/d, mean dose 32.3 mg/d) than with
placebo at the end of the study. There were, however, no
significant difference between paroxetine and placebo on the
VAS pain scores.
Sertraline
A 6-month comparative, prospective, randomized study of 70
fibromyalgia female patients compared the efficacy of sertraline
(50 mg/d for 6 months, n = 36) versus physical therapy (15
sessions of 1 W/cm
2 ultrasonography on the cervical trigger
points plus physical therapy, n = 34). Patients treated with
sertraline had a better outcome in terms of pain, morning
stiffness, and sleep disorders, than the group treated with
ultrasonography and physical therapy (Gonzalez-Viejo et al
2005).
Fluvoxamine
No published placebo-controlled trials are available so far.
The results of studies on SSRIs have, in general, been
disappointing. Efficacy, if it exists, appears to be quite modestNeuropsychiatric Disease and Treatment 2006:2(4) 543
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and the evidence, at best, inconsistent. Consequently this
class of drugs is considered by many to be less efficacious
than TCAs (Littlejohn and Guymer 2006).
Selective norepinephrine reuptake
inhibitors
A possible explanation for the decreased efficacy of the SSRIs
compared with the TCAs could reside in the absence of
noradenergic activity of the former. Reboxetine is a specific
inhibitor of the reuptake of NE, used in a number of countries
as an antidepressant (Preskorn 2004).
Reboxetine
In a case series, depressed patients with FMS experienced
relief of pain symptoms when treated with the noradrenergic
antidepressant reboxetine. Significant relief of pain occurred
before any significant improvement in mood symptoms (Krell
et al 2005).
Obviously further studies with selective NE reuptake
inhibitors such as reboxetine or atomoxetine are required
before any conclusions can be drawn.
Serotonin and norepinephrine reuptake
inhibitors
Venlafaxine
Although several open studies of venlafaxine in the treatment
of FMS have suggested a reduction of FMS symptoms
(Dwight et al 1998; Dryson 2000; Sayar et al 2003), a 6-week,
placebo-controlled trial has demonstrated that venlafaxine (75
mg/d) (n = 45) was ineffective on pain measured with a visual
analogue scale (Zijlstra et al 2002) compared to placebo (n =
45). It is important to note here that at the dose of venlafaxine
used in this study only the reuptake of 5-HT is likely to be
inhibited. There have been no studies at higher doses, which
are likely to inhibit both monoamine transporters.
Duloxetine
In a randomized, double blind, placebo-controlled trial
conducted on 207 subjects (89% women) with FMS, with or
without current major depressive disorder, subjects were
assigned to receive duloxetine 60 mg twice a day (n = 104),
which is a higher dose than the antidepressant dose, or placebo
(n = 103) for 3 months (Arnold et al 2004b). Duloxetine was
found to be better than placebo in FIQ total score and the FIQ
subscore, stiffness, but not in the other FIQ subscores (pain,
fatigue, morning tiredness). There were more responders
(defined as a reduction of at least 50% in the self-rating Brief
Pain Inventory average pain severity score) with duloxetine
than with placebo. This reduction was significant only in
female patients.
In a second study (Arnold et al 2005) the efficacy of
duloxetine in FMS was assessed in a 12-week, randomized,
double-blind, placebo-controlled trial in 354 female patients
with FMS. Patients received duloxetine 60 mg once daily (qd)
(n = 118), duloxetine 60 mg twice daily (bid) (n = 116), or placebo
(n = 120). There were significantly more responders (defined
in this study as a reduction of at least 30% on the Brief Pain
Inventory average pain severity score) in both duloxetine-
treated groups compared with placebo (duloxetine 60 mg qd,
55% responders, p < 0.001; duloxetine 60 mg bid, 54%, p =
0.002; placebo, 33% responders). Compared with patients on
placebo, patients treated with duloxetine 60 mg qd or duloxetine
60 mg bid also had significantly greater improvement on a
number of other outcome measures. In both studies,
duloxetine was well tolerated, and its effect on FMS symptoms
was independent of its effect on mood (Arnold et al 2004b,
2005). There was no major difference between the two doses
(60 and 120 mg/d).
Milnacipran
An open study (Nagaoka et al 2004) of the effect of milnacipran
(30–100 mg/d) on 20 patients with FMS found that pain and
general symptomatology were significantly improved at the
end of the study.
In a double blind, placebo-controlled trial 125 patients with
FMS were randomized, in a 3:3:2 ratio, to receive milnacipran
twice daily, milnacipran once daily, or placebo (Gendreau et al
2005). Two weeks baseline were followed by 4 weeks flexible
dose escalation (up to 200 mg/d), followed by a further 8 weeks
at a constant fixed dose, with 81% of once daily (qd) and 92%
of twice daily (bid) patients reaching the target dose of 200
mg/d. The primary end-point was reduction of global pain,
reported by using an electronic diary. The mean weekly pain
intensity decreased with time in the placebo group and both
milnacipran groups but the reduction was significantly greater
with twice-daily milnacipran than with placebo. Over 70% of
patients treated with milnacipran, either bid or qd, reported
overall improvement compared with 38% of those in the
placebo group (p < 0.01). Of patients treated twice daily with
milnacipran, 37% reported at least 50% reduction in pain
intensity, compared with 14% of placebo-treated patients
(p < 0.05). Fatigue, stiffness, and global well-being assessed
by using the FIQ subscales, were significantly improved in
both milnacipran groups, compared with the placebo group.
Response rates for patients receiving milnacipran were similarNeuropsychiatric Disease and Treatment 2006:2(4) 544
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in patients with and without comorbid depression, whereas
patients with depression had a greater response to placebo
than non-depressed patients. The greatest drug–placebo
difference was therefore found in the non-depressed patients.
Milnacipran was well tolerated and 84% of all patients treated
with milnacipran escalated to the highest dose (200 mg/day)
with no tolerability problems.
Other dual-acting compounds
Mirtazapine
Mirtazapine acts primarily as a α2-adrenergic receptor
antagonist and as such has indirect effects on both
serotonergic and noradrenergic neurotransmission (Szegedi
and Schwertfeger 2005). It is thus considered to be a dual
acting antidepressant albeit by a mechanism different from
the SNRIs. In 26 patients with FMS who completed a 6-week
open study with mirtazapine, 10 (38%) responded with a
reduction of at least 40% of the initial levels of pain, fatigue
and sleep disturbances (Samborski et al 2004). However, since
this was an open trial, double-blind placebo-controlled studies
are required to confirm these results.
Conclusion
Thus theoretical considerations and empirical observations
suggested the utility of antidepressants in the treatment of
FMS. Extensive clinical trials have produced convincing
evidence for the efficacy of TCAs (Table 1) as an effective
treatment option for patients suffering from FMS, whereas
the usefulness of SSRIs is unclear. Among the TCAs tested,
amitriptyline has been most studied and its efficacy has been
unequivocally demonstrated even though its effect size is
limited. The SNRIs, duloxetine and milnacipran, have also
demonstrated a clinical benefit in placebo-controlled trials.
Venlafaxine, on the other hand, was inactive (Zijlstra et al
2002). At the dose used, 75 mg/d, however, venlafaxine would
be expected only to block the uptake of 5-HT and thus for this
study venlafaxine should be considered as a SSRI.
A characteristic feature common to amitriptyline,
duloxetine, and milnacipran, which differentiates them from
the SSRIs is their ability to block the reuptake of both NE and
5-HT. It has been suggested that this dual mechanism of action
could be involved in the relief of pain and other symptoms in
FMS (Briley and Moret 2003).
There is evidence for modified serotonergic and
noradrenergic neurotransmission in FMS. The evidence for
modifications of the 5-HT system, however, is more extensive
than that for NE neurotransmission.
Reduced levels of the 5-HT metabolite, 5-hydroxyindole
acetic acid, have been reported in the cerebrospinal fluid (CSF)
of FMS patients compared with controls (Houvenagel et al
1990; Russell et al 1992a,b; Legangneux et al 2001). Serum
levels of 5-HT and tryptophan are similarly lower in patients
with FMS than in control subjects (Russell et al 1989; Alnigenis
and Barland 2001). An increased density of 5-HT receptors on
platelets in patients with FMS (Russell et al 1992b) and
abnormal transport of serum tryptophan (Yunus et al 1990),
which have also been reported, indicate a general disturbance
of serotonergic neurotransmission. Interestingly, however,
tryptophan depletion in FMS patients had no effect on their
pain severity (Schwarz et al 2003).
Evidence for a noradrenergic disturbance in FMS includes
decreased levels of the NE metabolite, 3-methoxy, 4-hydroxy
phenylglycol (MHPG), in FMS patients (Russell et al 1992a;
Legangneux et al 2001) although Yunus et al (1992) found no
changes in plasma and urinary catecholamines in FMS patients.
Direct injection of NE causes pain in about 80% of FMS
patients compared with only about 10% of patients suffering
from rheumatoid arthiritis, used as controls (Martinez-Lavin
et al 2002). In addition the intensity of the induced pain in
FMS patients was greater than the control groups. On the
basis of these data the authors suggested that FMS might be
the result of a sympathetic hyperactivity.
Evidence for an important role of NE in pain relief in general
has come from a study in non-depressed patients with chronic
back pain which showed that the NE selective antidepressant,
maprotiline, produced significantly more pain relief than either
placebo or the SSRI, paroxetine (Atkinson et al 1999).
Considerable animal data also confirm the involvement of
both 5-HT and NE in the pathogenesis of chronic pain and its
relief by antidepressants (Tura and Tura 1990; Sierralta
et al 1995; Fishbain et al 2000).
The involvement of the two monoamine systems in the
control of pain has a clear neuroanatomical basis. Both
serotonergic and noradrenergic systems have projections
ascending to various parts of the brain and descending to the
spinal cord. Serotonergic cell bodies, located in the raphe
nucleus, send projections to various parts of the brain such
as the frontal cortex, basal ganglia, limbic areas, and
hypothalamus where they mediate specific functions (control
of mood, movement, anxiety) and behaviors (eating, sexual
activity, feeling of pleasure). The cell bodies of the
noradrenergic neurons, located in the locus coeruleus, projectNeuropsychiatric Disease and Treatment 2006:2(4) 545
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to the frontal cortex, the limbic areas and the hypothalamus,
and also to specific areas in the frontal cortex where they
regulate attention and cognition. In addition to these
ascending serotonergic and noradrenergic pathways, neurons
in the raphe nucleus and the locus coeruleus also project to
the spinal cord (Wall and Melzack 1999) where they serve to
inhibit input from the periphery. There is thus an involvement
of both 5-HT and NE in the mediation of endogenous analgesic
mechanisms via the descending inhibitory pain pathways in
the brain and spinal cord (Basbaum and Fields 1978; 1984;
Clark and Proudfit 1993; Millan 2002). A dysfunction of these
5-HT- and NE-mediated descending pain-inhibitory pathways
can therefore result in heightened sensitivity to pain
(hyperalgesia) and even in the induction of pain (allodynia),
and is a potential mechanism for the pain experienced by
patients with FMS.
It could be argued that the FMS patients treated with
antidepressants feel relief from pain and other symptoms as a
result of the effect of these drugs on their depression. It has
been shown, however, that the effect of duloxetine is similar
in patients with FMS with or without depression (Arnold
et al 2004) and that the effect of milnacipran is greater in non-
depressed FMS patients (Gendreau et al 2005). In addition,
TCAs and SNRIs are effective in different chronic pain
syndromes independently of the presence of depression
(Salerno et al 2002; Briley 2004).
It is now generally accepted (Littlejohn and Guymer 2006)
that SSRIs are not as effective for overall improvement of
FMS symptoms as drugs that block the reuptake of both
5-HT and NE in a relatively balanced way. Among the
antidepressants, duloxetine and milnacipran, which are both
undergoing active clinical development for an indication in
FMS, appear to provide the best therapeutic option. They
have efficacy which is, at least, similar to amitriptyline and a
far superior tolerability. How these compounds will compare
with the non-antidepressant, pregabalin, which is also in
development in this indication (Crofford et al 2005), remains
to be seen.
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